Document Type : Review Articles
Authors
1
Pharmaceutical Chemistry Department, Faculty of Pharmacy, Nahda University in Beni-Suef (NUB), Beni-Suef 62513, Egypt.
2
Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, 61519-Minia, Egypt
3
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Nahda University, Beni Suef 62513, Egypt.
4
Medicinal Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt.
5
Medicinal Chemistry Department, Faculty of Pharmacy, Minia University.
Abstract
In recent years, the use of quinazoline and its derivatives as structural scaffolds has shown significant promise in drug design. These compounds have shown significant biological efficacy in the treatment of a variety of diseases, including cancer. Quinazoline has shown a significant reduction in adverse effects and improved treatment effectiveness, making it a very attractive candidate for further investigation and advancement in therapeutic interventions. This review provides a focus on the use of small-molecule targeted therapy. The discussion briefly introduces the epidermal growth factor receptor tyrosine kinase (EGFR TK), its mutations, and the development of innovative molecules in this domain. Furthermore, the current review digs into the concept of multi-targeted anticancer agents, particularly on quinazoline-based compounds that can obstruct several targets. Notably, these targets include EGFR/VEGFR dual inhibitors, EGFR/HDAC dual inhibitors, and a variety of other EGFR-related targets.
Keywords
Main Subjects
)
View on SCiNiTO